AI Summary Scores: Intraday / Swing / Long scores are synthesized from multi-factor analysis for each timeframe. They summarize current conditions discussed in the report and do not constitute trading recommendations.
Intraday Trend Score: A 0–100 composite from the Trend Explorer™ analytics engine used for ranking and comparison. It describes current conditions and is not a forecast.
Trend Status: A rules-based label (Bullish / Mixed / Bearish) derived from signal confluence (trend structure, momentum, and positioning). It indicates alignment, not expected return.
Last
$5.71
+$0.08 (+1.42%) 12:58 PM ET
Prev closePrevC$5.63
OpenOpen$5.70
Day highHigh$5.79
Day lowLow$5.67
VolumeVol251,674
Avg volAvgVol405,346
On chart
Interval
Intervals apply to 1D & 5D.
Intervals apply to 1D & 5D.
Scale: Linear
Overlays
Panels
Style
Scale: Linear
Presets
Tools
Tickers only (no ^ indexes). Add up to 5.
Mkt cap
$1.17B
Sector
Healthcare
AI report sections
BULLISH
IVA
Inventiva S.A.
No AI report section text found yet for this symbol.
Volume vs average
Intraday (cumulative)
−14% (Below avg)
Vol/Avg: 0.86×
RSI
48.09(Neutral)
Neutral (40–60)
0255075100
MACD momentum
Intraday
+0.00 (Strong)
MACD: 0.00 Signal: 0.00
Short-Term
+0.03 (Strong)
MACD: -0.18 Signal: -0.21
Long-Term
-0.00 (Weak)
MACD: -0.30 Signal: -0.30
Intraday trend score
51.00
LOW41.00HIGH51.00
Latest news
IVA•12 articles•Positive: 3Neutral: 9Negative: 0
NeutralGlobeNewswire Inc.• Na
Inventiva annonce le dépôt de son Document d’Enregistrement Universel 2025 et de son Rapport Annuel 2025 (« Form 20-F »)
Inventiva, a clinical-stage biopharmaceutical company, has filed its 2025 Universal Registration Document with the AMF and its Form 20-F with the SEC. The company reported €4.5 million in revenues for 2025 and held €99.3 million in cash and €131.6 million in short-term deposits as of December 31, 2025. Inventiva is developing lanifibranor, a pan-PPAR agonist, for the treatment of MASH (metabolic dysfunction-associated steatohepatitis) in its Phase 3 NATiV3 clinical trial.
IVAbiopharmaceuticalMASH treatmentlanifibranorPhase 3 clinical trialfinancial resultscash position
Sentiment note
The article is primarily a regulatory filing announcement with basic financial metrics. While the company maintains a solid cash position (€230.9 million combined) and is progressing with Phase 3 trials, the article lacks forward-looking statements, clinical trial results, or strategic updates that would indicate positive or negative momentum. The tone is factual and informational rather than highlighting achievements or concerns.
NeutralGlobeNewswire Inc.• Na
Inventiva announces filing of its 2025 Universal Registration Document and 2025 Annual Report on Form 20-F
Inventiva, a clinical-stage biopharmaceutical company, announced the filing of its 2025 Universal Registration Document with the French AMF and its 2025 Annual Report on Form 20-F with the SEC. The company reported 2025 revenues of €4.5 million and cash/short-term deposits totaling €230.9 million as of December 31, 2025. Inventiva continues to evaluate lanifibranor, a pan-PPAR agonist, in the NATiV3 Phase 3 clinical trial for MASH treatment.
The article is primarily a regulatory filing announcement with standard financial disclosures. While the company maintains a solid cash position (€230.9 million) and is progressing with its Phase 3 trial, the modest revenue (€4.5 million) and routine nature of the filing announcement do not indicate significant positive or negative developments. The tone is factual and informational rather than highlighting breakthrough results or concerning setbacks.
NeutralGlobeNewswire Inc.• Na
Inventiva Schedules the Publication and Presentation of its 2025 Full-Year Financial Results
Inventiva, a clinical-stage biopharmaceutical company developing oral therapies for MASH treatment, announced it will release its 2025 full-year financial results on March 30, 2026, followed by a management conference call on March 31, 2026. The company is currently evaluating lanifibranor, a pan-PPAR agonist, in the NATiV3 Phase 3 clinical trial.
The announcement is a routine disclosure of financial results timing and conference call details. There is no new clinical data, regulatory updates, or material developments mentioned that would indicate positive or negative sentiment. The tone is purely informational regarding investor communication logistics.
NeutralGlobeNewswire Inc.• Na
Inventiva annonce la publication et la présentation de ses résultats financiers annuels 2025
Inventiva, a biopharmaceutical company developing oral therapies for MASH treatment, announced it will publish its 2025 annual financial results on March 30, 2026, followed by an earnings conference call on March 31, 2026. The company is currently evaluating lanifibranor, a pan-PPAR agonist, in a Phase 3 clinical trial for treating adult patients with metabolic dysfunction-associated steatohepatitis.
The announcement is procedural in nature, simply notifying investors of upcoming financial results publication and conference call dates. No material clinical, financial, or operational developments are disclosed that would warrant positive or negative sentiment. The tone is informational without indication of positive or negative outcomes.
NeutralGlobeNewswire Inc.• Inventiva
Inventiva publie ses résultats financiers préliminaires pour l’exercice 2025¹
Inventiva, a clinical-stage biopharmaceutical company developing oral therapies for MASH, reported preliminary 2025 financial results showing €99.3 million in cash and equivalents plus €131.6 million in short-term deposits. The company generated €4.5 million in revenue and consumed €104.6 million in operating cash flows. Following a $172.5 million US public offering and structured financing, Inventiva estimates its liquidity will support operations until mid-Q1 2027, or mid-Q3 2027 if warrant tranches are fully exercised.
The company maintains adequate liquidity with €230.9 million in total liquid assets and secured additional $172.5 million through US public offering, supporting operations into 2027. However, revenue declined 51% year-over-year to €4.5 million, operating cash burn increased 22% to €104.6 million, and the company remains pre-commercial with no approved products. The financial position is stable but dependent on clinical trial success and future financing.
NeutralGlobeNewswire Inc.• Na
Inventiva reports preliminary 2025¹ fiscal year financial results
Inventiva, a clinical-stage biopharmaceutical company, reported preliminary 2025 financial results showing cash and cash equivalents of €99.3 million plus €131.6 million in short-term deposits. The company generated €4.5 million in revenues and used €104.6 million in operating activities. Following a U.S. public offering raising $172.5 million and structured financing, Inventiva estimates cash runway until mid-Q1 2027, or mid-Q3 2027 if Tranche 3 warrants are fully exercised. R&D expenses focused on lanifibranor development for MASH treatment amounted to €86.9 million.
While the company successfully raised significant capital ($172.5M) and maintains adequate liquidity until Q1 2027, it remains a clinical-stage company with no approved products, negative operating cash flow of €104.6M, and declining revenues (€4.5M vs €9.2M prior year). The company faces execution risks with its pivotal NATiV3 trial and will require additional capital or warrant exercises to extend runway beyond Q1 2027. The financial position is stable but dependent on clinical trial success and future financing.
PositiveGlobeNewswire Inc.• Na
Inventiva présentera au Guggenheim Emerging Outlook : Biotech Summit 2026
Inventiva announced that its CEO Andrew Obenshain will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11-12, 2026 in New York. The company will also hold individual meetings during the conference. Inventiva is developing lanifibranor, a small molecule oral therapy currently in Phase 3 clinical trials for the treatment of MASH (metabolic dysfunction-associated steatohepatitis).
The company's CEO participation in a major biotech conference demonstrates investor confidence and provides a platform for discussing clinical progress with lanifibranor in Phase 3 trials. Conference presentations typically signal positive momentum and are used to communicate progress to investors and stakeholders.
PositiveGlobeNewswire Inc.• Inventiva
Inventiva to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
Inventiva announced that CEO Andrew Obenshain will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11, 2026, in New York City. The company will also hold one-on-one meetings during the conference. Inventiva is a clinical-stage biopharmaceutical company developing oral therapies for MASH treatment, currently evaluating lanifibranor in the NATiV3 Phase 3 clinical trial.
IVAInventivaGuggenheim Emerging Outlook Biotech SummitCEO participationlanifibranorMASH treatmentPhase 3 clinical trialbiopharmaceutical
Sentiment note
The company's CEO has been invited to speak at a major industry conference (Guggenheim Biotech Summit), which indicates recognition and visibility in the biotech sector. This type of conference participation is typically viewed as a positive development for investor relations and market positioning.
NeutralGlobeNewswire Inc.• Inventiva
Results of the Votes of the Combined Shareholders’ General Meeting of November 27, 2025
Inventiva held its Combined Shareholders' Meeting on November 27, 2025, where most resolutions were adopted, except for the 5th resolution regarding share capital increases for a company savings plan.
The meeting proceeded normally with most resolutions passed, though the 5th resolution was rejected. The company continues its clinical-stage development of MASH treatments.
NeutralGlobeNewswire Inc.• Inventiva
Résultats des Votes de l’Assemblée Générale Mixte des Actionnaires Réunie le 27 novembre 2025
Inventiva held its Mixed Shareholders Meeting on November 27, 2025, where most resolutions were adopted, except for the 5th resolution related to capital increases for employee savings plans.
The company successfully held its shareholders meeting with most resolutions passed, but the rejection of the 5th resolution suggests some internal disagreement about capital structure
PositiveGlobeNewswire Inc.• Inventiva
Information relating to the stabilization activities carried out in the context of its recent offering
Inventiva completed a public offering of 38,961,038 American Depositary Shares on Nasdaq, with underwriters fully exercising their option to purchase additional shares, bringing total proceeds to approximately $172.5 million.
Successfully completed a public offering, raised significant capital, and fully exercised underwriters' option, indicating strong market interest and financial strategy
NeutralGlobeNewswire Inc.• Inventiva
Informations relatives aux activités de stabilisation menées dans le cadre de sa récente offre au public
Inventiva reported stabilization activities following its recent public offering of 38,961,038 American Depositary Shares on the Nasdaq Global Market, with Piper Sandler acting as the stabilization agent.
The company is reporting routine financial disclosure about its public offering and stabilization activities without indicating significant positive or negative performance
News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks App
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal
